Invea Therapeutics

Invea Therapeutics is a biotechnology company focused on developing innovative oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs). They utilize artificial intelligence and machine learning, specifically InveniAI's AlphaMeld Platform, to decode the complex mechanisms driving these diseases. Their approach involves mining genes, drugs, diseases, and symptoms to create IMID-focused networks, identifying potential targets and accelerating drug discovery. Their pipeline includes INVA8001, a selective inhibitor of chymase for mast cell-driven inflammation, targeting conditions like chronic urticaria and atopic dermatitis, and INVA8003, which targets ASC for inflammasome inhibition, aiming to treat various IMIDs.